Biocon Biologics (BBL), a global biosimilars company and subsidiary of Biocon , has expanded its strategic partnership with Civica, to launch a new private-label Insulin Glargine medicine in the United States. The collaboration seeks to broaden access to high-quality, affordable insulin therapies for the country’s 38.4 million diabetes patients.
Under the multi-year agreement, Biocon Biologics will manufacture and supply Insulin Glargine to Civica, which will market and distribute the medicine in the U.S. under a separate Civica label and trade dress. In California, the product will be sold under the CalRx brand. The company will also continue to commercialise its own Insulin Glargine-yfgn, approved by the U.S. Food and Drug Administration (FDA) in 2021 as the first interchangeable biosimilar insulin.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics , said, “Biocon Biologics is committed to expanding access to affordable, high-quality insulins in the U.S. and globally. By extending our collaboration with Civica to include Insulin Glargine, we are building on our differentiated approach to enhance patient access through multiple channels, in alignment with our mission.”
No technology transfer is involved in the agreement, and Biocon Biologics retains ownership of the intellectual property and marketing authorization associated with Insulin Glargine.
The announcement builds on a previous partnership between the two companies, under which Biocon Biologics supplies Civica with Insulin Aspart drug substance for U.S. manufacturing.
Ned McCoy, President and CEO, Civica, Inc., said, “We are pleased to expand our partnership with Biocon Biologics, which helps us achieve a significant milestone in our insulin initiative. Today’s announcement allows us to realize our goal of bringing insulin to people who need it at a transparent low price.”
Biocon Biologics is among the world’s leading insulin producers, providing over 9.2 billion doses globally with a portfolio that includes basal, mixed, and rapid-acting insulins. |
